(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...

Drug resistance in solid tumors remains a major obstacle in oncology, frequently leading to treatment failure and disease relapse. A central contributor to ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 ...

Cancer plasticity allows tumor cells to change their identity, evade therapies, and adapt to environmental pressures, contributing to treatment resistance and metastasis. New research is targeting ...

Hyperthermia, a cancer treatment using controlled heat to kill tumor cells, shows promise but faces limitations due to some ...

New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in ...

A study initiated by a University of Arizona Comprehensive Cancer Center physician-scientist defined for the first time how loss of the Y chromosome in male immune cells negatively affects immune ...

Pheast Therapeutics, a clinical-stage biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the U.S. Food ...